Answers are grounded in this paper and cite their sources.
This viewpoint discusses the transition to expert panels for decision-making at the FDA, suggesting implications for credibility and legality.
This Viewpoint discusses the lawfulness and credibility of the US Food and Drug Administration’s recent move to using expert panels rather than advisory committees for decision-making.
No takes yet. Share an insight, caveat, or question.
Daval et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: